Citius Pharmaceuticals In... (CTXR)
Citius Pharmaceuticals Statistics
Share Statistics
Citius Pharmaceuticals has 9.36M shares outstanding. The number of shares has increased by -95.24% in one year.
| Shares Outstanding | 9.36M |
| Shares Change (YoY) | -95.24% |
| Shares Change (QoQ) | 11.21% |
| Owned by Institutions (%) | 0.04% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 1,300 |
| FTD / Avg. Volume | 0.42% |
Short Selling Information
The latest short interest is 755.91K, so 8.08% of the outstanding shares have been sold short.
| Short Interest | 755.91K |
| Short % of Shares Out | 8.08% |
| Short % of Float | 8.52% |
| Short Ratio (days to cover) | 3.33 |
Valuation Ratios
The PE ratio is -55.21 and the forward PE ratio is 0.16. Citius Pharmaceuticals's PEG ratio is -12.15.
| PE Ratio | -55.21 |
| Forward PE | 0.16 |
| PS Ratio | 0 |
| Forward PS | 0 |
| PB Ratio | 31.06 |
| P/FCF Ratio | -77.18 |
| PEG Ratio | -12.15 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Citius Pharmaceuticals.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.4, with a Debt / Equity ratio of 0.
| Current Ratio | 0.4 |
| Quick Ratio | 0.17 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.01 |
| Interest Coverage | 0 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,714,166.91 |
| Employee Count | 23 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 576K |
| Effective Tax Rate | -1.48% |
Stock Price Statistics
The stock price has increased by -95.93% in the last 52 weeks. The beta is 1.19, so Citius Pharmaceuticals's price volatility has been higher than the market average.
| Beta | 1.19 |
| 52-Week Price Change | -95.93% |
| 50-Day Moving Average | 1.31 |
| 200-Day Moving Average | 7.57 |
| Relative Strength Index (RSI) | 25.77 |
| Average Volume (20 Days) | 310,419 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | n/a |
| Net Income | -39.43M |
| EBITDA | n/a |
| EBIT | n/a |
| Earnings Per Share (EPS) | -0.23 |
Balance Sheet
The company has 3.25M in cash and 262.87K in debt, giving a net cash position of 2.99M.
| Cash & Cash Equivalents | 3.25M |
| Total Debt | 262.87K |
| Net Cash | 2.99M |
| Retained Earnings | -201.37M |
| Total Assets | 120.7M |
| Working Capital | -26.48M |
Cash Flow
In the last 12 months, operating cash flow was -28.2M and capital expenditures 0, giving a free cash flow of -28.2M.
| Operating Cash Flow | -28.2M |
| Capital Expenditures | n/a |
| Free Cash Flow | -28.2M |
| FCF Per Share | -0.16 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CTXR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CTXR is $54.5, which is 7469.4% higher than the current price. The consensus rating is "Buy".
| Price Target | $54.5 |
| Price Target Difference | 7469.4% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Stock Splits
The last stock split was on Jun 9, 2017. It was a backward split with a ratio of 1:15.
| Last Split Date | Jun 9, 2017 |
| Split Type | backward |
| Split Ratio | 1:15 |
Scores
| Altman Z-Score | -3.71 |
| Piotroski F-Score | 3 |